内窥镜超声引导下胃肠吻合术（EUS-GE）逐渐被用于无法手术的恶性胃出口梗阻（GOO）患者。然而，EUS-GE对患者生活质量（QoL）的影响尚未进行前瞻性评估。2019年8月至2021年5月，西班牙四家中心连续评估了接受EUS-GE的无法切除的恶性GOO患者，使用欧洲研究和治疗癌症组织（EORTC）问卷EORTC-QLQ-C30在基线和术后1个月进行评估。通过电话进行集中的随访。采用胃出口梗阻评分系统（GOOSS）评价口服，将临床成功定义为GOOSS≥2。使用线性混合模型评估基线和30天QoL分数之间的差异。 共招募了64名患者，33名男性（51.6％），年龄中位数为77.3（IQR：65.5-86.5）岁。最常见的诊断是胰腺（35.9％）和胃（31.3％）腺癌。37（57.9％）名患者的基线ECOG表现状态评分为2/3。 61名（95.3％）患者在48小时内恢复口服，术后中位数住院时间为3.5（IQR：2-5）天。30天临床成功率为83.3％。全球健康状态量表的临床显着增加为21.6（95％CI：11.5-31.7）分，并出现明显的恶心/呕吐，疼痛，便秘和食欲不振的改善。 EUS-GE已被证明可缓解无法切除的恶性肿瘤患者的GOO症状，使其能够快速口服并出院。它还提供了从基线到30天的临床相关的QoL分数显着提高。 版权所有©2023美国胃肠内窥镜学会。由Elsevier Inc.发布。保留所有权利。

Endoscopic ultrasound guided gastroenterostomy (EUS-GE) is increasingly used for malignant gastric outlet obstruction (GOO) in inoperable patients. However, the impact of EUS-GE on patient quality of life (QoL) has not been evaluated prospectively.Consecutive patients with unresectable malignant GOO who underwent EUS-GE between August 2019 and May 2021 at four Spanish centers were prospectively assessed using the European Organization for Research and Treatment of Cancer (EORTC) questionnaire EORTC-QLQ-C30 at baseline and 1 month after the procedure. Centralized follow-up via telephone calls was undertaken. Gastric Outlet Obstruction Scoring System (GOOSS) was used to assess oral intake, defining clinical success as a GOOSS≥2. Differences between baseline and 30 days QoL scores were assessed using a linear mixed model.Sixty-four patients were enrolled, 33 (51.6%) males, median age 77.3 (IQR: 65.5-86.5) years. The most common diagnoses were pancreatic (35.9%) and gastric (31.3%) adenocarcinoma. Thirty-seven (57.9%) patients presented a 2/3 baseline ECOG performance status score. Oral intake was restarted within 48 hours in 61 (95.3%) patients and the median post-procedure hospital stay was 3.5 (IQR: 2-5) days. The 30-day clinical success rate was 83.3%. A clinically significant increase of 21.6 (95% CI: 11.5-31.7) points in the global health status scale was documented, with significant improvements in nausea/vomiting, pain, constipation and appetite loss.EUS-GE has proven to relieve GOO symptoms in patients with unresectable malignancy, allowing rapid oral intake and hospital discharge. It also provides a clinically relevant increase in QoL scores at 30 days from baseline.Copyright © 2023 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.